Prosecution Insights
Last updated: November 04, 2026
Application No. 18/860,999

HOLLOW EMBOLIC MICROSPHERE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF

Non-Final OA §103§112
Filed
Oct 28, 2024
Priority
Apr 28, 2022 — CN 202210478407.X +1 more
Examiner
PRAGANI, RAJAN
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zhejiang Sci-Tech University
OA Round
1 (Non-Final)
53%
Grant Probability
Moderate
1-2
OA Rounds
1y 5m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allowance Rate
34 granted / 64 resolved
-6.9% vs TC avg
Strong +70% interview lift
Without
With
+69.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
46 currently pending
Career history
123
Total Applications
across all art units

Statute-Specific Performance

§101
6.3%
-33.7% vs TC avg
§103
50.9%
+10.9% vs TC avg
§102
2.8%
-37.2% vs TC avg
§112
23.0%
-17.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 64 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of Group I (claims 20-23 and 31) in the reply filed on 09/08/2026 is acknowledged. The traversal is on the ground(s) of the following reasons: On pg 11-12, Applicant argues the restriction by pointing to specific embodiments of Dicarlo, while not considering the broader teachings of Dicarlo (e.g., “Dicarlo describes cavities and opening merely as optional additional structures”), as read onto claim 20, in terms of obviousness. Note that specific embodiments do not define the teachings: “Applicants erroneously point to specific embodiments expressly disclosed within the prior art reference as representing the sum total of information conveyed by each. Art is art, not only for what it expressly teaches, but also for what it would reasonably suggest to the skilled artisan, including alternative or non-preferred embodiments. Merck & Co. v. Biocraft Laboratories, 874 F.2d 804, 10 USPQ2d 1843 (Fed. Cir.), cert. denied, 493 U.S. 975 (1989).” A PHOSITA would understand that given DiCarlo’s teaching of an opening 55 ([0080], Figure 20) and/or a cavity 72, whereby the cavity is optionally sealed and/or loaded with a therapeutic ([0076], Figure 16), that a cavity and/or cavity-opening could be placed at the center of a spherical particle, in which DiCarlo teaches spherical particles [0004-0010, 0078]. On pg 12, Applicant argues DiCarlo’s thermally responsive deformable polymers are incompatible with Applicant’s claim scope. However, Applicant has not adequately explained how the suitable shape memory polymers for in vivo use, that include “elastomers” [0040] are different from the instant “biocompatible polymer material with viscoelasticity” (instant claim 20). Further note Dicarlo teaches some embodiments where the particle is formed entirely of materials that do no exhibit shape memory characteristics (“a non-shape memory material”) [0063], including absorbable polymers such as hyaluronic acid and hydrogels generally [0064] (i.e., recited in instant claim 42), further comprising natural materials such as alginate [0066] (i.e., recited in instant claim 42). On pg 12-13, Applicant argues that DiCarlo’s preparation method is fundamentally different than the instant Application. Even if this were the case, the restriction is based on a fundamental shared technical element between all claims, which in this case, is the instantly claimed composition of claim 20 (i.e., the restriction itself is based on the composition structure, and regardless of the process of making, and there is no product-by-process language in claim 20), that is found obvious based on Dicarlo alone. Thus collectively, the arguments are not found persuasive. Furthermore, see the related Prior Art of the 103 below that further demonstrates claim 1 to contain a shared technical element. The requirement is still deemed proper and is therefore made FINAL. Claims 24-30 and 32-37 are withdrawn from further consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected Group II-VII, there being no allowable generic or linking claim. Applicant timely traversed the restriction (election) requirement in the reply filed on 07/07/2026. Priority The present application is a National Stage entry of International application PCT/CN2023/091079 filed 04/27/2023, which claims the benefit of Foreign application CN202210478407.X filed 04/28/2022. Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55, although it is noted that no English translation was provided. Status of the Application Receipt is acknowledged of Applicant’s claimed invention, filed 10/28/2024, in the matter of Application N° 18/860,999. Said documents have been entered on the record. New claims 38-46 have been added to the claims. The Examiner further acknowledges the following: Claims 20-46 are pending. Claims 24-30 and 32-37 are withdrawn from consideration as directed to non-elected inventions. Claims 20-23, 31, and 38-46 are presented for examination and rejected as set forth below. Drawings The drawings are objected to because there is poor resolution and/or small illegible font in Fig 26, 27, 31-32, 36 38-39, 41, 46, 49, 53. Applicant is recommended to amend the drawings to improve overall resolution (i.e., at Applicant’s discretion). Corrected drawing sheets in compliance with 37 CFR 1.121(d) are required in reply to the Office action to avoid abandonment of the application. Any amended replacement drawing sheet should include all of the figures appearing on the immediate prior version of the sheet, even if only one figure is being amended. The figure or figure number of an amended drawing should not be labeled as “amended.” If a drawing figure is to be canceled, the appropriate figure must be removed from the replacement sheet, and where necessary, the remaining figures must be renumbered and appropriate changes made to the brief description of the several views of the drawings for consistency. Additional replacement sheets may be necessary to show the renumbering of the remaining figures. Each drawing sheet submitted after the filing date of an application must be labeled in the top margin as either “Replacement Sheet” or “New Sheet” pursuant to 37 CFR 1.121(d). If the changes are not accepted by the examiner, the applicant will be notified and informed of any required corrective action in the next Office action. The objection to the drawings will not be held in abeyance. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 46 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 46 recites “virus-like”, which is language that is subjective in nature, depending on what is considered “virus-like” (i.e., whole virus, inactivated virus, virus mimic, polynucleotide and/or polypeptide portion of a virus, etc., and there is no further defining of “virus-like” within the Specification). Further clarification and/or amendment is required. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 20-23, 31, 38-42, and 44-46, are rejected under 35 U.S.C. 103 as being unpatentable over Dicarlo (US20050095428A1). Applicant’s claims are directed to a hollow embolic microsphere, wherein: the hollow embolic microsphere has a spheroidal or hemispheroidal shape, an internal cavity and an opening structure, and the material of the hollow embolic microsphere is biocompatible polymer material with viscoelasticity. Furthermore, hemispheroidal shape is a broad definition of shape, and is interpreted of having at least half or more of the particle with a sphere shape. Note, for example, independent claim 20 does not have a typical transitional phrase, and therefore, the Examiner interprets the “hollow embolic microsphere” to “consist of “ (i.e., “is”) the additional structural limitations of the claim scope. Dicarlo teaches embolic compositions made of polymers (abstract, Dicarlo – claims 1-3 and 27) for the use to prevent or treat certain conditions in the body (e.g., deprive tumors, block hemorrhage, etc.) [0003]. Furthermore, the compositions comprise cross-linked polymers [0069]. Regarding claim 20 and 38: Dicarlo teaches embolic particles for use in the body [0003] made form shape memory material comprising polymers (Dicarlo – claims 1-2), whereby the final particle shape is non-limiting (e.g., spherical or non-spherical; see Fig 1B, including drawn structures 22) [0004-0010, 0078]. PNG media_image1.png 281 230 media_image1.png Greyscale Further there is the obviousness of providing an opening 55 ([0080], Figure 20) and/or a cavity 72, whereby the cavity is optionally sealed and/or loaded with a therapeutic ([0076], Figure 16). See Figures below. PNG media_image2.png 202 302 media_image2.png Greyscale PNG media_image3.png 328 530 media_image3.png Greyscale Thus, a PHOSITA would understand that given Dicarlo’s teaching of an opening 55 ([0080], Figure 20) and/or a cavity 72, whereby the cavity is optionally sealed and/or loaded with a therapeutic ([0076], Figure 16), that a cavity and/or cavity-opening could be placed at the center of a spherical particle [0004-0010, 0078]. Regarding claim 21: Dicarlo teaches structural projections/bumps [0067] (e.g., projection 59 or Fig 20) and indentations/concavity [0060, 0080] (reads on bulge toward the opening structure or cavity center of instant claim 21). Regarding claim 22 and 41: Dicarlo shows a cylindrical object in Figure 16: a ratio of width to height of about 1:1; a ratio of inner diameter to outer diameter of about 1:2 (i.e., also about 50 % compared to the instant range of 1 to 95% of claim 41); a ratio of wall thickness to particle size of about 1:10 (reads on the structural parameters of instant claim 22), whereby it would be obvious to a PHOSITA to develop a spherical variant of this based on DiCarlo’s teaching of a non-limiting particle shape (e.g., spherical or non-spherical; see Fig 1B) [0004-0010, 0078]. Note that non-limiting variability of shape is built into Dicarlo’s design and is optimized based on intended use and outcome (i.e., including the obvious limitations of spherical structures, hollow features, etc. [0004-0010, 0078] or different sizes [0079-0080]). Regarding claim 23: Dicarlo teaches that the microsphere incorporates polyester (Dicarlo – claim 27). Regarding claim 31: Dicarlo teaches incorporation of active agents [0071]. Regarding claim 39-40: Dicarlo teaches a particle size diameter of 1000 micron (reads on “50 to 2000 um” of instant claim 39 and “one or a combination of two or more groups of…particle size of 900 to 1200 um” of instant claim 40) [0049], whereby the final particle shape is non-limiting, including different varieties of particles in a given compositional mixture (e.g., spherical or non-spherical; see Fig 1B) [0004-0010, 0078] or different sizes [0079-0080], and may contain openings and cavities, in which an embodiment is considered where a material sealant degrades or dissolves to release a therapeutic agent ([0080], Figure 20; [0076], Figure 16). Regarding claim 42: Dicarlo teaches some embodiments where the particle is formed entirely of materials that do no exhibit shape memory characteristics (“a non-shape memory material”) [0063], including absorbable polymers such as hyaluronic acid and hydrogels generally [0064], further comprising natural materials such as alginate [0066]. Regarding claim 44: Dicarlo further teaches active agents such as the hemostatic agent Avitene® (a microfibrillar collagen (e.g., 40-60 micron particles) (reads on polymer micron particles of claim 44) [0083] or MRI-visible nanocrystalline metallic particles [0074]. Regarding claim 45: Dicarlo teaches nanocrystalline Fe3O4 (aka, Iron (II,III) Oxide or Magnetite)(reads on nano-iron oxide) [0074]. Regarding claim 46: Dicarlo teaches a non-limiting variety of therapeutic agents, including anti-cancer drugs such as paclitaxel, bifunctional molecules consisting of an antibody and a cytotoxin (reads on “antibody conjugated drug”), etc. [0070-0071]. In summary, Dicarlo teaches embolic particles made form shape memory material (Dicarlo – claims 1-2), whereby the final particle shape is non-limiting (e.g., spherical or non-spherical) [0004-0010], and further there is the obviousness of providing an opening 55 [0080]. It must be remembered that “[w]hen a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious.” KSR v. Teleflex, 127 S.Ct. 1727, 1740 (2007) (quoting Sakraida v. A.G. Pro, 425 U.S. 273, 282 (1976)). “[W]hen the question is whether a patent claiming the combination of elements of prior art is obvious,” the relevant question is “whether the improvement is more than the predictable use of prior art elements according to their established functions.” (Id.). Thus, Dicarlo teaches the combination of art-known elements (i.e., spherical particles, surface holes, cavities, materials, active ingredients, etc.), according to their disclosed beneficial properties (i.e., embolic treatment and/or controlled drug delivery) with the resultant product nothing more than one would expect from their combination (i.e., resolution of embolic related conditions and/or disorders). Claims 20-23, 31 and 38-46 are rejected under 35 U.S.C. 103 as being unpatentable over Dicarlo (US20050095428A1), as applied to claims 20-23, 31, 38-42, and 44-46, and in further view of Zhu (US20190231924A1). As discussed above, the Dicarlo teaches nearly all of the elements and motivation for the obviousness of the instant claim scope (i.e., spherical particles, surface holes, cavities, polymeric materials, active ingredients, cross-linked polymers, etc.). However, DiCarlo does not teach the crosslinking agent and amount/ratio (instant claim 43). Zhu teaches microspherical embolic agent comprising crosslinked hyaluronic acid (abstract), that employs crosslinkers such as divinyl sulfone, 1,4-butanediol diglycidyl ether, etc. [0017]. The amount of crosslinker used is 0.2-2 vol %, with an example of 0.1 g/mL sodium hyaluronate (100 mg/mL = about 10 v/v%) reacting with 1% 1,4-butanediol diglycidyl ether [0027], providing a ratio of crosslinking agent to polymer material ratio of 1:10 (or 0.1:10) (reading on the range of 0.0001:1 to 10:1 of instant claim 43). Zhu teaches beneficial characteristics of chemically-modified polymers, as embolic agents [0005-0006]: “Chemically modified hyaluronic acid has improved anti-degradation capability and retains the unique properties of hyaluronic acid such as biocompatibility, high viscoelasticity, and being free of side effect.” Zhu further teaches the method produces embolic spheres that are uniform and smooth [0007], which can better occlude distal blood vessels and can greatly decrease the coefficient of friction in the blood vessel during the embolization [0005]. It would have been prima facie obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the broader teachings of Dicarlo that describe embolic particles of a non-limiting shape (e.g. spherical) and made of polymer (e.g. hyaluronic acid), to incorporate the crosslinking agents of Zhu, because Zhu teaches microspherical embolic agents comprising crosslinked hyaluronic acid that employs crosslinkers such as divinyl sulfone, 1,4-butanediol diglycidyl ether, etc. [0017], whereby Dicarlo teaches embolic particles, where the particle is formed entirely of materials that do no exhibit shape memory characteristics (“a non-shape memory material”) [0063], including absorbable polymers such as hyaluronic acid and hydrogels generally [0064], further comprising natural materials such as alginate [0066], and also cross-linked polymers [0069]. Furthermore, the chemical modifying cross-linking approach by Zhu improves anti-degradation capability, retains the beneficial polymeric properties, is free of side effect, and produces uniform/smooth embolic spherical particles, which demonstrates better performance during the embolization [0005-0007], providing explicit motivation for this modification. Claims 20-23, 31, 38-42, and 44-46, are further rejected under 35 U.S.C. 103 as being unpatentable over Dicarlo (US20050095428A1), and in further view of Mu (CN112023115A – machine translation provided; published 12-04-2020, as compared to the instant priority date of 04/28/2022; provided in IDS filed 10/28/2024). As discussed above, the Dicarlo teaches nearly all of the elements and motivation for the obviousness of the instant claim scope (i.e., spherical particles, surface holes, cavities, materials, active ingredients, cross-linked polymers etc.). Mu further explicitly provides a more visually similar structural embodiment (i.e., compared to the intended structure of the instant claim scope, as described by the Figure 1 of the Drawings). Mu teaches the obviousness of hollow particle forms (abstract) based on crosslinked polymers [0056-0057] such as chitosan [0028]. Mu shows that different payloads (e.g., Bletilla striata polysaccharide granules [0011, 0021], that improve anti-tumor therapeutic effect on the lesion site, via slow release [0011]) can be carried within the spherical particle. See Figure 3 below. PNG media_image4.png 346 398 media_image4.png Greyscale Mu teaches matrix 11 is a polymer-based material [0027] (e.g., albumin, gum, chitosan), without any general limiting restrictions of polymer type [0028]. It would have been prima facie obvious for one of ordinary skill in the art before the effective filing date of the claimed invention to modify the broader teachings of Dicarlo that narrow the specific particle shape to a hollow sphere of Mu because Mu teaches hollow spherical particles as suitable vehicles for delivery of anti-cancer drugs, whereas Dicarlo teaches the structural elements of spherical particles, surface holes, cavities. Furthermore, application of a hole to the surface of the spherical shell, as taught by Dicarlo, would provide an exit for active ingredient into the desired location of the body, because Dicarlo teaches an embodiment that is considered where a material sealant degrades or dissolves to release a therapeutic agent ([0080], Figure 20; [0076], Figure 16). Correspondence Any inquiry concerning this communication or earlier communications from the examiner should be directed to RAJAN PRAGANI whose telephone number is (703)756-5319. The examiner can normally be reached 7a-5p EST (M-Th). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush can be reached on 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /R.P./Examiner, Art Unit 1614 10/1/2026 /SEAN M BASQUILL/Primary Examiner, Art Unit 1614
Read full office action

Prosecution Timeline

Oct 28, 2024
Application Filed
Oct 19, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12765546
PELARGONIC ACID-BASED HERBICIDE COMPOSITIONS
4y 2m to grant Granted Oct 20, 2026
Patent 12734117
WATER-IN-OIL EMULSION COMPOSITION
4y 7m to grant Granted Sep 15, 2026
Patent 12734122
PROCESS FOR PREPARING SURFACTANT SOLUTIONS WITH N-ACYL AMINO ACID SALTS
3y 3m to grant Granted Sep 15, 2026
Patent 12721793
O/W EMULSION AND W/O EMULSION INVERTED THEREFROM, AND PERSONAL CARE COMPOSITION CONTAINING SAME
3y 10m to grant Granted Sep 01, 2026
Patent 12714767
HYBRID-HYDROGELS COMPRISING DECELLULARIZED EXTRACELLULAR MATRIX
3y 11m to grant Granted Aug 25, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
53%
Grant Probability
99%
With Interview (+69.8%)
3y 6m (~1y 5m remaining)
Median Time to Grant
Low
PTA Risk
Based on 64 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month